Apr 20, 2026, 8:40 AMbusinesswire.comPPTDF
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
Company announcementsCompany details
KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Daisuke Okajima, hereinafter “Asahi Kasei Therapeutics”), its collaboration partner, has initiated a Phase 1 clinical trial*1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered throu.
